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Abstract: The etiology of pain in osteoarthritis is multifactoral, and includes mechanical and 
inflammatory processes. Intra-articular injections of hyaluronans (HAs) are indicated when 
non-pharmacological and simple analgesics have failed to relieve symptoms. The HAs appear to 
reduce pain by restoring both mechanical and biomechanical homeostasis in the joint. There are 
five FDA-approved injectable preparations of HAs: Hyalgan®, Synvisc®, Supartz®,   Orthovisc® 
and Euflexxa®. They all appear to relieve pain from 4 to 14 weeks after injection and may have 
disease-modification properties. Although several randomized controlled trials have established 
the efficacy of this treatment modality, additional high quality randomized control studies with 
appropriate comparison are still required to clearly define the role of intra-articular HA   injections 
in the treatment of osteoarthritis.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis. It has been reported 
that 40% of people over the age of 80 will have at least one joint involved and 
27 million people in the United States have clinical OA.1,2 OA is a slowly evolving 
process, characterized by joint pain, stiffness and loss of range of motion. Weight 
bearing usually worsens the pain and it is improved with rest. OA results from 
a complex interaction of biomechanical, biochemical and genetic factors and is 
characterized by degradation of cartilage and hypertrophy of bone. The etiology of 
OA remains unknown; however, significant risk factors have been identified with 
OA development.1,3 These include joint trauma, hypermobility, mal-alignment and 
genetic abnormalities. On physical examination patients usually have a swollen joint 
with warmth, palpable osteophytes, crepitus with movement, tenderness and reduced 
range of motion. The treatment of OA includes non-pharmacological interventions 
such as patient education, physical therapy, weight loss and low-impact exercises.4–7 
Pharmacological treatment options include acetaminophen, non-steroidal anti-
inflammatory drugs (NSAIDs), topical NSAIDs, glucosamine and/or chondrotin 
sulfate and intra-articular (IA) corticosteroids. Opioid and non-narcotic analgesics 
may be prescribed in refractory pain patients. IA hyaluronans (HAs) have recently 
been used for the treatment of painful knee joints with OA.8 Surgical intervention 
should be considered only after pharmacological and non-pharmacological treatment 
have failed.3 The purpose of this review is to address the role of IA HAs treatment 
for pain in OA of the knee.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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Pain mechanism in OA
The etiology of pain in the joint with OA is complex but a 
brief summary of the pathophysiology of pain production 
is helpful to understand the role of HAs in its treatment.1 
Studies have identified the three major types of pain. Acute 
pain is directly associated with the activation of peripheral 
nerve receptors. Chronic pain is associated with an ongoing 
inflammation of peripheral tissues.9 When there is a sig-
nificant chronic pain, damage occurs to the pain pathways 
either peripherally or centrally, which results in the third 
type of pain, neuropathic.10 Synovial joints are innervated 
by nerves that originate in primary sensory neurons located 
in the dorsal root ganglion.11 The tissues of synovial joints 
that are innervated by nerve endings are the capsule, liga-
ments, synovial membrane and subchondral bone. Hyaline 
cartilage does not have nerve endings. The nerves of the 
synovial joint are sensitive to the detection of both noxious 
and non-noxious stimuli. Activation of the nerve endings 
can begin with any mechanical, chemical, or thermal pro-
cess. The pathophysiology of OA involves the release of a 
large number of inflammatory mediators and these directly 
act on the nerve endings and reduce their threshold to pain 
recognition.11 The result is an enhanced discharge of nerve 
impulses that are perceived as a painful stimuli. IA HAs have 
been shown to have a pain-reduction effect through a number 
of mechanisms which will be discussed later.
Hyaluronans
Hyaluronan or hyaluronic acid (HA) is a complex gly-
cosaminoglycan composed of repeated disaccharide units 
to form a linear polymer. It is widely present in mammalian 
tissues and has the highest concentration in synovial fluid. 
Its function in the diarthrodial joint is both mechanical and 
metabolic. HA provides important viscoelasticity and lubri-
cating properties to synovial fluid, thereby reducing articular 
cartilage wear.10 Further, HA molecules restrict large plasma 
protein from entering into the synovial fluid while facilitating 
the passage of small molecules into the joint for maintenance 
of nutrition.12 The synthesis of HA in OA is disrupted by 
increased levels of pro-inflammatory cytokines, free radi-
cals and proteinases, resulting in an HA with a significantly 
reduced molecular weight, more molecular polydisaccha-
rides, and a reduction in synovial fluid viscoelasticity.12 This 
abnormal hyaluronic acid increases the potential for articular 
cartilage wear and accelerates progression of the disease. 
The progression of OA results from the disruption of the 
mechanical, biochemical and homeostasis of the diarthro-
dial joint, in part provided by ultra-high molecular weight 
HA. HA functions in articular cartilage as a supramolecular 
aggregate to retain proteoglycans, aggrecan and link protein. 
It therefore acts as a scaffold for these important extracellular 
matrix molecules. Loss of this normal HA disrupts cartilage 
matrix stability and perpetuates the destruction of the articu-
lar cartilage. Mechanically HA provides viscoelastic proper-
ties to the joint allowing for normal fluid flow, lubrication 
and smooth joint motion. When the ultra-molecular weight 
HA is enzymatically cleaved by the increased levels of the 
proteinases observed in OA, the lower-molecular-weight 
HA no longer can maintain the mechanical integrity of the 
joint. Further, this lower-weight HA may be proinflamma-
tory, further accelerating the disease. The goals of IA HA 
injections are to improve function, reduce pain and possibly 
modify disease activity. Potential disease-modifying activi-
ties of the HA include promotion of healing and repair by 
stimulating chondrocyte growth, decreasing apoptosis and 
stimulating synthesis of cartilage matrix components: col-
lagen, proteoglycans and endogenous hyaluronans.12–14 There 
are data that suggests a potential inhibition of the synthesis 
and activity of the chondrodegradating enzymes, eg, metal-
loproteinases as well as the inhibition of matrix destructive 
inflammatory processes.15–17
Exogenous HA with a molecular weight of 500 to 
4000 kDa increases synovial fluid viscosity and enhances 
shock absorption and the lubricating capabilities of synovial 
fluid.18 HA has been shown to have an effect on reducing pain 
by several mechanisms.19 HA binds neuropeptides, creating a 
boundary layer around nocireceptors which is one mechanism 
to reduce pain. Additional mechanisms that potentially can 
reduce pain in OA include inhibition of inflammatory media-
tors, eg, cytokines and prostaglandin. HA has been shown to 
stimulate endogenous HA synthesis by synovial sites through 
CD 44 receptor binding.12,20 Exogenous HA downregulates 
matrix metalloproteinase-3 expression and inhibit metal-
loproteinase synthesis which results in decreased cartilage 
destruction. Exogenous HA restores metabolic homeostasis 
thereby enhancing synovial fluid flow and reducting pain. The 
synergistic effect of exogenous HAs reduces the mechani-
cal, chemical or thermal noxious stimuli to the innervated 
tissues of the synovial joint restoring normal homeostasis 
and reducing pain and stiffness.
HAs in clinical use
There are currently five FDA-approved injectable prepara-
tions of HAs used for the painful knee in OA: Synvisc®, 
Hyalgan®, Supartz®, Orthovisc® and Euflexxa®. Table 1 
summarizes their product characteristics.21–24Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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The available HAs range in molecular weight from 
500 to 6000 kDa. HAs with molecular weights less than 
500 kDa have not been effective in either pain relief or 
improvement of function. The active ingredients are sodium 
hyaluronate in a concentration of about 20 mg per dose. 
The recommended number of injections per course range 
from a single injection for Synvisc to five for Hyalgan or 
Supartz. The total dose of HA per series varies from 45 mg 
for Orthovisc to 125 mg for Supartz. There have been no well 
done randomized controlled head-to-head studies reported, 
so conclusions on the outcomes of different dosages are 
difficult to make. Hyalgan, Synvisc, Supartz and Orthovisc 
are naturally derived products from purified HA extracted 
from rooster comb. Euflexxa and the recently introduced 
Supartz are made by a different process in which their HA 
is derived from an engineering-based process that extracts 
HA from fermented bacterial sources.
The current guidelines for the treatment of OA of the 
knee suggest the use of IA HAs for the treatment of pain 
in patients who have failed to respond adequately to non-
  pharmacological therapy as well as simple analgesics.1,3–5,7 
IA HAs are contra-indicated if there is known hypersensitiv-
ity to HA preparations, if there is a IA infection or a skin 
problem in the area of the injection site. As a class the HAs 
are relatively safe with no significant systemic adverse events. 
There have been no drug interactions reported.25
Five meta-analyses have been published on IA HA 
treatment in knee OA with the primary outcome being 
pain relief.25–29 Table 2 summarizes these meta-analyses. 
In general the studies support the efficacy of IA HAs in 
reducing pain; however, the data indicate only a small but 
clinically important effect. The outcome metrics of most 
studies   centered upon the improvement of pain measures, 
eg, WOMAC A or VAS scores; however, in some studies 
when function was also assessed usually by WOMAC Scores, 
similar parallel improvements of function and stiffness were 
seen. The improvement did not last beyond 14 weeks after 
treatment and the effect size was no more than 0,3. Issues 
that reduce the value of these meta-analyses include the lack 
of head-to-head comparisons, the high variability because of 
different outcome measures and the use of different outcome 
scales. One study has suggested that IA HA injections provide 
a longer-term pain benefit than IA corticosteroids.8 The recent 
introduction of Synvisc I, a single 6 mm injection of Hyalan 
G-F 20, was shown to be effective in a randomized, double-
blind placebo controlled trial. This is a unique formulation 
and demonstrated after one injection a significant decrease 
in WOMAC A pain scores.30
The 2006 Cochrane Review reviewed 76 trials, and is 
the most comprehensive review to date.7 Many different 
HA products were examined for effects from 1 to 52 weeks. 
In assessing the pooled effect size in comparison to placebo 
at 1 to 4 weeks after treatment, the reduction in pain was 
  significant and physical function also improved as joint 
  stiffness declined. There is considerable diversity in the 
outcomes between many of these trials. Previous data had 
suggested that the higher-molecular-weight products had 
a greater efficiency, especially in pain relief, but recent 
studies indicated that the pooled effect size of higher 
molecular weights were not more effective in relieving 
pain.14,15,18,19,25,31 Further, the data suggested that pain reduc-
tion diminished with time and was no longer significant after 
14 weeks. A number of trials have compared IA HAs to IA 
corticosteroids.4,32–34 The data indicate that IA corticosteroids 
significantly improveed pain during the first 4 weeks after 
injection but that IA HAs were shown to be more effective 
Table 1 US-approved hyaluronan (HA) therapies: summary of product profiles
Product distributor Manufacturing Active ingredient Number 
injections per 
course
Molecular 
weight (kDa)
Labeling 
precaution on 
efficacy/safety
Hyalgan (Sanofi-Aventis) Naturally derived, 
purified HA
1% sodium 
hyaluronate (20 mg)
3 or 5 500–730 No
Synvisc (Genzyme 
Biosurgery)
Hylan polymers 
derived from HA
0.8% sodium  
hyaluronate 
derivative (16 mg)
1 (6 mL) or  
3 (2 mL)
6000 + gel No
Supartz (Smith and 
Nephew)
Naturally derived, 
purified HA
1% sodium 
hyaluronate (25 mg)
3 or 5 620–1170 Yes
Orthovisc (DePuy Mitek) Naturally derived, 
purified HA
0.7% sodium 
hyaluronate (30 mg)
3 or 4 1100–2900 Yes
Euflexxa (Ferring) Fermented, bacterial 
derived HA
1% sodium  
hyaluronate (20 mg)
3 2400–3600 Yes
Notes: Product profiles based on package insert of Hyalgan (2001), Synvisc (2006), Synvisc I (2008), Supartz (2004), Orthovisc (2005), Euflexxa (2005).Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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from 5 to 13 weeks post-injection. Pain relief was greatest 
following IA corticosteroids at 2 weeks, but not at 4 weeks 
after injection. By contrast IA HAs demonstrated superior 
reduction in pain at 8 weeks and continued to be significant 
until 14 weeks after the injections.
IA HAs have an excellent safety profile with few serious 
side-effects.25 Systemically there is no differences observed 
in gastrointestinal and cardiovascular events between HAs 
and controls. There have been reported a number of local 
adverse events such as transient pain and swelling at the 
injection site and in some circumstances, IA injections of 
HAs were followed by a greater frequency of pain and 
swelling when compared to placebo.9,35–37 Pseudoseptic 
reactions after injections have been reported primarily with 
Hylan G-F 20 treatment.38 Pseudosepsis is characterized by 
a severe inflammatory response in the joint with significant 
cellular infiltration and painful effusion occurring within 
72 hours after the injection. It usually occurs after a second 
or third injection in the treatment course and appears similar 
to an infectious process or a gouty response so that sepsis 
or pseudogout should be excluded. The synovial fluid may 
have a high number of mononuclear cells with some neu-
rophils, but with an increased number of eosinophils and 
macrophages.6 It generally is not self limiting and requires 
some clinical intervention such as arthrocentesis and an IA 
steroid injection, with the addition of oral NSAIDs. If there is 
a concern about infection, while awaiting cultures, one should 
consider administering prophylactic oral antibiotics. If the 
condition does continue to deteriorate, intravenous   antibiotics 
may be indicated. If a chronic granuloma develops, surgi-
cal intervention may be required. Data from clinical and 
pre-clinical studies suggest that there is an immunological 
basis for this reaction; however, more studies in this area are 
needed to substantiate this mechanism and their long-term 
consequences.38
IA HAs are indicated in the US for use in knee OA. 
However, there have been a number of physician directed 
uses of HA in other joints. Qvistgaard in a randomized 
controlled trial of HA compared to isotonic saline in hip 
OA demonstrated a significant improvement in pain and 
an overall improvement in clinical activities.39 Another 
study utilizing a population of patients who were total 
hip replacement candidates demonstrated a significant 
improvement in both pain and Harris Hip Scores.40,41 More 
randomized control trials are necessary to establish the 
risk/benefit of the use of IA HAs in hip OA. Other joints 
have been studied including the carpal-metacarpal joint, 
shoulder and ankle.42–44 The results have been variable 
and it is difficult to conclude anything from these studies 
without further randomized control trials. One orthopedic 
application is the injection of HA in the post-arthroscopy 
period to enhance pain and accelerate rehabilitation. One 
recent study evaluated the safety and efficacy of a high-
molecular-weight sodium hyaluronate after a knee arthros-
copy for treatment of a symptomatic meniscus tear.45 The 
study utilized 3 injections after arthroscopy and randomized 
patients into a group treated with the IA HA compared to 
a group using only acetaminophen, up to 1000 mg 4 times 
a day. The patients in the treated groups 3 and 6 months 
after surgery had significantly less pain and more flexion 
than the comparative control group. This is an area that is 
fertile for additional randomized controlled trials.
Table 2 intra-articular hyaluronan therapy in knee osteoarthritis: summary of meta-analyses
Reference Lo27 Wang29 Arrich26 Modawal28 Bellamy25
Total no. of 
studies
22 20 22 11 76
Efficacy outcome 
measures
effect size (change  
from baseline pain  
vs placebo)
Mean difference, 
ASPiD vs placebo
wMD in pain 
during/after 
exercise (vAS) vs  
control
vAS wMD in pain on 
weight bearing  
vs placebo
Key pooled 
results
effect size: 0.32 
(P , 0.001)
Mean difference 
for ASPiD: 13.4%
wMD 10–14 wk: 
-4.3 mm (P = 0.013) 
wMD 22–30 wk: 
-7.1 mm (P = 0.013)
wMD 
5–7 wk: 17.6 
(95% Ci, +7.5, +28.0) 
8–12 wk: 18.1 
(95% Ci, +6.3, +29.9) 
15–22 wk: 4.4 
(95% Ci, -15.3, 24.1)
% Change 5–13 wk: 
+26% for pain; 
+23% for function
Conclusion Small treatment 
effect
Safe and effective Not effective in 
measured outcomes
Moderately effective at 
5–10 wk, not effective 
at 15–22 wk
effective treatment for 
pain, function, pt, global 
assessment at 5–13 wk
Abbreviations: ASPiD, adjusted sum of pain intensity differences; wMD, weighted mean difference; vAS, visual analog scale; pt, patient.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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In conclusion pain is a central symptom of OA and 
requires an integrated approach to it’s treatment. Both non-
pharmacological and pharmacological treatments offer the 
best chance for pain relief. Pharmacological treatments 
include NSAIDs, cox-2 inhibitors, opioids, anti-inflammatory 
creams and IA corticosteroids. IA corticosteroids have been 
shown to be effective in relieving pain during the first 2 weeks 
after treatment. IA HA injections have a longer onset of action 
and longer duration of effect. The exact mechanism of action 
is still to be delineated, although it is clear that IA HA reduces 
pain through its effect on peripheral pain receptors as well 
as an impact on the synovial tissue and its role in enhancing 
the viscoelastic properties of synovial fluid. Although there 
have been many studies, there still is a need for additional 
high quality, randomized control trials with placebos or 
comparators to clearly delineate the role of IA HA in the 
treatment of pain in OA. The use of IA HA in other joints 
requires additional well structured clinical studies.
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